Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy

AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of ophthalmology 2021-06, Vol.105 (6), p.844-849
Hauptverfasser: Park, Dong-Geun, Jeong, Seongyong, Noh, Donghyoun, Sagong, Min
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 849
container_issue 6
container_start_page 844
container_title British journal of ophthalmology
container_volume 105
creator Park, Dong-Geun
Jeong, Seongyong
Noh, Donghyoun
Sagong, Min
description AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.
doi_str_mv 10.1136/bjophthalmol-2020-316837
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2429058265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2529679785</sourcerecordid><originalsourceid>FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</originalsourceid><addsrcrecordid>eNqNkD1PwzAURS0EoqXwF1AkFpaAP2o7GVHFl1SpCwxMluM8K6mSONjO0H-PqxaEmJisd3Xu89NBKCP4jhAm7qutG5vY6K53XU4xxTkjomDyBM3JUhQpkuUpmmOMZU6IIDN0EcI2jVQQeY5mjEoqJWNz9LEZY9vrLrPdBIOBzOsImbPZ2Ljo6t2g-9ZksQGvx11mnc9M492QMgND9KkYwLsppNj51nmI7eBGHZvdJTqzugtwdXwX6P3p8W31kq83z6-rh3VesULGvJCYghW45tLURDAiQVTM8nJZ1aauuMDcQmlAc2sMB6hLgZnUxFa4JlRYtkC3h72jd58ThKj6NhjoOj1AOkzRJS0xL6jgCb35g27d5Id0naKclkKWsthTxYEy3oXgwarRJ0V-pwhWe_3qt361168O-lP1-vjBVPVQ_xS_fSeAHYCq3_5_7Rdw-peJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2529679785</pqid></control><display><type>article</type><title>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</title><source>PubMed Central (PMC)</source><creator>Park, Dong-Geun ; Jeong, Seongyong ; Noh, Donghyoun ; Sagong, Min</creator><creatorcontrib>Park, Dong-Geun ; Jeong, Seongyong ; Noh, Donghyoun ; Sagong, Min</creatorcontrib><description>AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2020-316837</identifier><identifier>PMID: 32727733</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Demographics ; Eye diseases ; Ischemia ; Medical imaging ; Photodynamic therapy ; Photoreceptors ; Vascular endothelial growth factor</subject><ispartof>British journal of ophthalmology, 2021-06, Vol.105 (6), p.844-849</ispartof><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</citedby><cites>FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</cites><orcidid>0000-0003-4140-5015 ; 0000-0001-9175-9642</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32727733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Dong-Geun</creatorcontrib><creatorcontrib>Jeong, Seongyong</creatorcontrib><creatorcontrib>Noh, Donghyoun</creatorcontrib><creatorcontrib>Sagong, Min</creatorcontrib><title>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><description>AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.</description><subject>Demographics</subject><subject>Eye diseases</subject><subject>Ischemia</subject><subject>Medical imaging</subject><subject>Photodynamic therapy</subject><subject>Photoreceptors</subject><subject>Vascular endothelial growth factor</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkD1PwzAURS0EoqXwF1AkFpaAP2o7GVHFl1SpCwxMluM8K6mSONjO0H-PqxaEmJisd3Xu89NBKCP4jhAm7qutG5vY6K53XU4xxTkjomDyBM3JUhQpkuUpmmOMZU6IIDN0EcI2jVQQeY5mjEoqJWNz9LEZY9vrLrPdBIOBzOsImbPZ2Ljo6t2g-9ZksQGvx11mnc9M492QMgND9KkYwLsppNj51nmI7eBGHZvdJTqzugtwdXwX6P3p8W31kq83z6-rh3VesULGvJCYghW45tLURDAiQVTM8nJZ1aauuMDcQmlAc2sMB6hLgZnUxFa4JlRYtkC3h72jd58ThKj6NhjoOj1AOkzRJS0xL6jgCb35g27d5Id0naKclkKWsthTxYEy3oXgwarRJ0V-pwhWe_3qt361168O-lP1-vjBVPVQ_xS_fSeAHYCq3_5_7Rdw-peJ</recordid><startdate>202106</startdate><enddate>202106</enddate><creator>Park, Dong-Geun</creator><creator>Jeong, Seongyong</creator><creator>Noh, Donghyoun</creator><creator>Sagong, Min</creator><general>BMJ Publishing Group LTD</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4140-5015</orcidid><orcidid>https://orcid.org/0000-0001-9175-9642</orcidid></search><sort><creationdate>202106</creationdate><title>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</title><author>Park, Dong-Geun ; Jeong, Seongyong ; Noh, Donghyoun ; Sagong, Min</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b387t-8702ef60d57cd16317e6b3f594bdcdb5605fe9cea5fcc5eed96037a1fb0d126f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Demographics</topic><topic>Eye diseases</topic><topic>Ischemia</topic><topic>Medical imaging</topic><topic>Photodynamic therapy</topic><topic>Photoreceptors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Dong-Geun</creatorcontrib><creatorcontrib>Jeong, Seongyong</creatorcontrib><creatorcontrib>Noh, Donghyoun</creatorcontrib><creatorcontrib>Sagong, Min</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Dong-Geun</au><au>Jeong, Seongyong</au><au>Noh, Donghyoun</au><au>Sagong, Min</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy</atitle><jtitle>British journal of ophthalmology</jtitle><addtitle>Br J Ophthalmol</addtitle><date>2021-06</date><risdate>2021</risdate><volume>105</volume><issue>6</issue><spage>844</spage><epage>849</epage><pages>844-849</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><abstract>AimsTo investigate the lowest effective fluence rate of photodynamic therapy (PDT) for treating chronic central serous chorioretinopathy (CSC).MethodsFifty-one eyes of 51 patients with chronic CSC were randomly treated with 30% (n=15), 40% (n=16) or 50% (n=17) of the standard-fluence rate of PDT and followed up for 12 months. The success rate, recurrence rate, mean best-corrected visual acuity (BCVA), central foveal thickness (CFT), subfoveal choroidal thickness (SFCT), integrity of the outer retinal layer and complications were evaluated at baseline and at the follow-up periods after PDT.ResultsThe rate of complete subretinal fluid (SRF) resolution in the 30%-fluence, 40%-fluence and 50%-fluence groups was 60.0%, 81.2% and 100.0%, respectively, at 3 months (p=0.009), and 80.0%, 94.0% and 100.0%, respectively, at 12 months (p=0.06). The recurrence rate in the 50%-fluence group was lower than that in the 30%- and 40%-fluence groups at 12 months (30% vs 50%, 40% vs 50%; p=0.002, p=0.030, respectively (log-rank test)). The mean BCVA improved significantly 12 months after PDT only in the 40%- and 50%-fluence groups (p=0.005, p=0.003, respectively). Mean CFT and SFCT decreased significantly at 12 months in the three groups. The rate of complications did not differ significantly among the three groups.ConclusionsA 50%-fluence rate of PDT seems to be the most effective for treating chronic CSC, considering the low recurrence rate and high rate of complete SRF resolution, compared with other low-fluence PDT.Trial registration numberNCT01630863.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>32727733</pmid><doi>10.1136/bjophthalmol-2020-316837</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4140-5015</orcidid><orcidid>https://orcid.org/0000-0001-9175-9642</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0007-1161
ispartof British journal of ophthalmology, 2021-06, Vol.105 (6), p.844-849
issn 0007-1161
1468-2079
language eng
recordid cdi_proquest_miscellaneous_2429058265
source PubMed Central (PMC)
subjects Demographics
Eye diseases
Ischemia
Medical imaging
Photodynamic therapy
Photoreceptors
Vascular endothelial growth factor
title Optimal fluence rate of photodynamic therapy for chronic central serous chorioretinopathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T14%3A25%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Optimal%20fluence%20rate%20of%20photodynamic%20therapy%20for%20chronic%20central%20serous%20chorioretinopathy&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Park,%20Dong-Geun&rft.date=2021-06&rft.volume=105&rft.issue=6&rft.spage=844&rft.epage=849&rft.pages=844-849&rft.issn=0007-1161&rft.eissn=1468-2079&rft_id=info:doi/10.1136/bjophthalmol-2020-316837&rft_dat=%3Cproquest_cross%3E2529679785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2529679785&rft_id=info:pmid/32727733&rfr_iscdi=true